Insilico Medicine Nominates ISM1354, Reports 287% Revenue Growth and First Profitable Half-Year Since Listing

Insilico Medicine (HKEX: 3696), a clinical-stage drug discovery company, announced the nomination of ISM1354, an AI-driven preclinical candidate targeting GIPR for obesity and related disorders. The company also reported a 287% year-over-year revenue increase for the first half of 2026, reaching approximately $106 million, and its first profitable half-year since listing, with adjusted net profit exceeding $51 million. Cumulative signed deal value since 2021 has reached nearly $11 billion.